论文部分内容阅读
【据《Hepatology》2015年4月报道】题:索非布韦联合聚乙二醇干扰素加利巴韦林治疗最初直接抗病毒药物治疗失败的HCV基因1型患者(作者Pol S等)目前对于直接抗病毒药物治疗未获得持续病毒学应答的患者再治疗还没有被广泛研究。法国巴黎第五大学的Pol等实施一项开放性试验,评估索非布韦联合聚乙二醇干扰素(PEG-IFN)加利巴韦林治疗HCV基因1型患者的有效性和安全性,这些患者曾参与一个或多个Gilead研究性直接抗病毒药物加利巴韦林联合或不联合PEG-IFN的研究。研究者在40个地方招募了80例
[Reported by April 2015 of Hepatology] SUBJECT: Combining peginterferon and ribavirin with sofosbuvir in patients with HCV genotype 1 who failed initial direct antiviral therapy (by Pol S, et al) Re-treatment of patients who have not achieved a sustained virologic response to direct antiviral therapy has not been extensively studied. Pol et al at the University of Paris in Paris, France, conducted an open-label trial assessing the effectiveness and safety of sofosbuvir plus PEG-IFN and ribavirin in the treatment of HCV genotype 1 patients, These patients have been involved in the study of one or more of Gilead’s investigational direct antiviral drug, ribavirin, with or without PEG-IFN. Researchers recruited 80 patients in 40 places